

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. API-01-059-US)

PATENT

RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

## INFORMATION DISCLOSURE STATEMENT

Asst. Commissioner for Patents  
Washington, D.C. 20231  
**Via Hand Delivery**

Dear Sir:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references are "prior art" within the meaning of 35 U.S.C. §102 or §103.

## CITED REFERENCES

### U.S. Patents

### Foreign Patent Documents

WO 98/45312

### Other Documents:

GIEBINK G S ET AL: Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: Immunogenicity and efficacy in experimental pneumococcal otitis media: The Journal of Infectious diseases, vol 167, no 2, February 1993, pages 347-355

CAMPAGNE G. ET AL: Safety and Immunogenicity of three doses of a Neisseria meningitidis A+ diphtheria conjugate vaccine in infants from Niger: Pediatric Infectious Disease Journal, Vol 19, no 2 Pages 144-150

PAOLETTI L C ET AL: Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine: Infection and Immunity, Vol 62, no 8 Pages 3236-3243

Respectfully Submitted,  
AVENTIS PASTEUR INC.

Date: Nov. 4, 2003

By:

T. Helen Payne  
T. Helen Payne  
Reg. No. 36,889

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Shee

1

of 2

**C complete if Known**

Application Number	10/054,638
Filing Date	01/22/02
First Named Inventor	Robert P. Ryall
Art Unit	1645
Examiner Name	Devri, Sarvamangala
Attorney Docket Number	API-01-059-US

**U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number	10/054,638
Filing Date	01/22/2003
First Named Inventor	Robert P. Ryall
Art Unit	1645
Examiner Name	Devi, Sarvamangala
Attorney Docket Number	API-01-059-US

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GIEBINK G S ET AL: Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: Immunogenicity and efficacy in experimental pneumococcal otitis media: The Journal of Infectious Diseases, vol 167, no 2, February 1993, pages 347-355	
		CAMPAGNE G. ET AL: Safety and Immunogenicity of three doses of a Neisseria meningitidis A+ diphtheria conjugate vaccine in infants from Niger: Pediatric Infectious Disease Journal, Vol 19, no 2 Pages 144-150	
		PAOLETTI L C ET AL: Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine: Infection and Immunity, Vol 62, no 8 Pages 3236-3243	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.